TB-PRACTECAL: THINK contributing to improve health, shorter treatment, quality of life for patients world-wide!
Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients London, 21 December 2022—A new all-oral, six-month treatment regimen is safer and more effective at treating multidrug-resistant tuberculosis (MDR-TB) than the current options for people with drug-resistant TB (DR-TB), according to the results of a Médecins Sans Frontières/Doctors Without Borders (MSF) study published in the New England Journal of Medicine today. These findings are a result of MSF’s TB-PRACTECAL, the first-ever multi-country, randomized, [...]